HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer

Detalles Bibliográficos
Autores principales: Yamaoka, Toshimitsu, Tsurutani, Junji, Sagara, Hironori, Ohmori, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653124/
https://www.ncbi.nlm.nih.gov/pubmed/33209639
http://dx.doi.org/10.21037/tlcr-20-578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653124/
https://www.ncbi.nlm.nih.gov/pubmed/33209639
http://dx.doi.org/10.21037/tlcr-20-578

Ejemplares similares